IDEAYA Biosciences (IDYA) Income from Non-Controlling Interests (2018 - 2021)
IDEAYA Biosciences (IDYA) reported Income from Non-Controlling Interests of -$46000.0 for Q3 2021, down 109.09% on a YoY basis from $506000.0 in Q3 2020, and down 1433.33% sequentially from -$3000.0 in Q2 2021.
IDEAYA Biosciences (IDYA) Income from Non-Controlling Interests (2018 - 2021) Analysis & Trends
IDEAYA Biosciences (IDYA) has 4 years of Income from Non-Controlling Interests data on file, last reported at -$46000.0 in Q3 2021.
- For the quarter ending Q3 2021, Income from Non-Controlling Interests fell 109.09% year-over-year to -$46000.0; the trailing twelve-month figure through Sep 2021 stood at -$84000.0 (down 95.35% YoY), and the FY2020 full-year result was -$58000.0, down 160.42% from the prior year.
- Income from Non-Controlling Interests fell to -$46000.0 in Q3 2021, from -$3000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $57000.0 in Q2 2020 to a low of -$65000.0 in Q1 2020.
- A 4-year average of -$1571.4 and a median of -$6500.0 in 2018 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests jumped 583.33% in 2019 and plunged 266.67% in 2020, its largest moves.
- Tracing IDYA's Income from Non-Controlling Interests over 4 years: stood at -$14000.0 in 2018, then advanced by 7.14% to -$13000.0 in 2019, then plunged by 115.38% to -$28000.0 in 2020, then slumped by 64.29% to -$46000.0 in 2021.
- Business Quant data shows IDYA's Income from Non-Controlling Interests at -$46000.0 in Q3 2021, -$3000.0 in Q2 2021, and -$7000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | - |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | IDEAYA Biosciences | 3.25 Bn | 2.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | -46,000.00 |
| Jun 30, 2021 | -3,000.00 |
| Mar 31, 2021 | -7,000.00 |
| Dec 31, 2020 | -28,000.00 |
| Sep 30, 2020 | -22,000.00 |
| Jun 30, 2020 | 57,000.00 |
| Mar 31, 2020 | -65,000.00 |
| Dec 31, 2019 | -13,000.00 |
| Sep 30, 2019 | 41,000.00 |
| Jun 30, 2019 | 29,000.00 |
| Mar 31, 2019 | 39,000.00 |
| Dec 31, 2018 | -14,000.00 |
| Sep 30, 2018 | 16,000.00 |
| Jun 30, 2018 | -6,000.00 |